Immunotherapies for Extensive-Stage SCLC

Author(s):

Ryan Haumschild, PharmD, MS, MBA,Anne Chiang, MD, PhD

Panelists discuss how immunotherapies like durvalumab and atezolizumab have emerged as promising treatments for extensive-stage small cell lung cancer (SCLC), complementing traditional chemotherapy, and explore the results of key trials such as CASPIAN and IMpower133 while considering patient selection, treatment algorithms, and management of adverse events associated with these novel therapies.

EP: 1.Introduction: Risk Factors and Characteristics Defining SCLC

EP: 2.Established Multidisciplinary Therapies for SCLC

Now Viewing

EP: 3.Immunotherapies for Extensive-Stage SCLC

EP: 4.Introducing Bispecifics for Extensive-Stage SCLC

EP: 5.Standard of Care Durvalumab for Limited-Stage SCLC

EP: 6.Additional Immunotherapies on the Horizon for LS-SCLC

EP: 7.Payer and Patient Education Considerations for SCLC

EP: 8.Biomarker Discovery and Exploration for SCLC

EP: 9.Key Takeaways on Recent Advances in SCLC

EP: 10.Therapies Beyond the Front Line for SCLC

EP: 11.Timing and Urgency Considerations in SCLC

Let’s discuss the extensive-stage setting first. Beyond chemotherapy, immunotherapies have also been investigated in small cell lung cancer (SCLC). What are the main differences between these 2 classes of medication, and why was it necessary to study these in SCLC?

Durvalumab has also shown to have positive results as a first-line treatment in extensive-stage lung cancer in the CASPIAN trial. Where does this treatment fit into your treatment algorithm?

What are the adverse events to monitor for, and how do you manage them?

Can you describe the results of the IMpower133 trial with atezolizumab in extensive-stage SCLC and how these impact your practice?

In which patients do you use atezolizumab?